Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast CancerDouglas Yee, Minetta C. Liu, Angela DeMichele et al.|JAMA Oncology|2020Cited by 225
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).Qamar J. Khan, Priyanka Sharma, Laura M. Spring et al.|Journal of Clinical Oncology|2020Cited by 68
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Jane Perlmutter, Claudine Isaacs et al.|npj Breast Cancer|2021Cited by 29
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E. Lang, Laura J. Esserman, Andres Forero‐Torres et al.|npj Breast Cancer|2022Cited by 27
Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trialBeverly Kyalwazi, Laura J. Esserman, Christina Yau et al.|Cancer Research|2022Cited by 3